Astrazeneca Pharma India Ltd

Astrazeneca Pharma India Ltd is rated Sell by MarketsMOJO. This rating was last updated on 02 Jan 2026. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 06 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Astrazeneca Pharma India Ltd has experienced a notable shift in its technical momentum, moving from a bearish to a mildly bearish trend as of early 2026. Despite a recent downgrade in its Mojo Grade from Hold to Sell, the stock’s mixed technical signals across key indicators such as MACD, RSI, Bollinger Bands, and moving averages suggest a complex outlook for investors navigating the Pharmaceuticals & Biotechnology sector.

Astrazeneca Pharma India Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a more pronounced bearish trend. Despite some bullish signals on longer-term indicators, the overall technical landscape suggests caution for investors as the stock contends with downward pressure amid mixed momentum indicators and a recent downgrade in its Mojo Grade to Sell.

Astrazeneca Pharma India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 April 2026, providing investors with the latest insights into its performance and outlook.

Astrazeneca Pharma India Ltd has experienced a notable shift in price momentum, reflected in a 5.21% gain on 15 Apr 2026, as technical indicators reveal a complex picture of mildly bearish to bullish signals across weekly and monthly timeframes. Despite a recent downgrade from Hold to Sell by MarketsMOJO, the stock’s long-term returns remain robust, outperforming the Sensex over multiple periods.

Astrazeneca Pharma India Ltd is rated Sell by MarketsMOJO. This rating was last updated on 02 Jan 2026. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 14 April 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.

Astrazeneca Pharma India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 Jan 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 03 April 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Astrazeneca Pharma India Ltd experienced a significant intraday decline on 27 Mar 2026, touching a low of Rs 7,825, down 7.02% from the previous close. The stock underperformed its sector and broader market indices amid widespread selling pressure and bearish technical signals.

Astrazeneca Pharma India Ltd is rated Sell by MarketsMOJO. This rating was last updated on 02 Jan 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 23 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Astrazeneca Pharma India Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The stock’s recent price action, combined with deteriorating moving averages and mixed signals from momentum oscillators, suggests caution for investors amid a challenging market backdrop.

Astrazeneca Pharma India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 Jan 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 12 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Astrazeneca Pharma India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Astrazeneca Pharma India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

AstraZeneca Pharma India Ltd. delivered a mixed performance in Q3 FY26 (Oct-Dec'25), with robust revenue growth overshadowed by significant margin compression and profit decline. The pharmaceutical major reported net profit of ₹32.59 crores, down 39.89% quarter-on-quarter from ₹54.22 crores in Q2 FY26, though up 5.64% year-on-year from ₹30.85 crores in Q3 FY25. The stock has declined 4.13% following the results announcement, trading at ₹8,696.15 and reflecting investor concerns about operational efficiency despite strong topline momentum.

Astrazeneca Pharma India Ltd is rated Sell by MarketsMOJO, with this rating last updated on 02 January 2026. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 07 February 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market standing.

Astrazeneca Pharma India Ltd has experienced a subtle shift in its technical momentum, moving from a bearish to a mildly bearish trend as of early 2026. Despite a modest day gain of 0.97%, the stock’s technical indicators present a complex picture, with some signals suggesting caution while others hint at potential stabilisation. This article analyses the recent technical parameter changes, key momentum indicators, and how Astrazeneca’s performance compares with broader market benchmarks.

Astrazeneca Pharma India Ltd is rated Sell by MarketsMOJO, with this rating last updated on 02 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 27 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.